// startup autopsy
Axial Biotech
Genetic scoliosis diagnostics that couldn't crack the reimbursement barrier
marketfitSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: Axial Biotech launched the ScoliScore test without securing broad insurance reimbursement, creating an adoption ceiling that made commercial scale impossible.
Key Events Timeline
FOUNDING
Axial Biotech founded in Salt Lake City to develop genetic diagnostics for musculoskeletal disorders, focusing on scoliosis.
FUNDING
Secured early funding to advance the ScoliScore genetic test through clinical validation studies.
FUNDING
Final funding round closed bringing total to $19.4M; ScoliScore test moved toward commercial launch.
PRODUCT LAUNCH
ScoliScore test commercially launched, offering genetic risk stratification for adolescent idiopathic scoliosis progression.
SHUTDOWN
Axial Biotech closed operations after failing to achieve sufficient reimbursement coverage and commercial traction for the ScoliScore test.
MEDIA_MENTION
Axial Biotech is permanently closed. If you feel this is an error, let us know. Overview · Predictions & Insights · Financials · Financial Details · Market